Compare Edwards Lifesciences Corporation Common Stock (EW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Summit Therapeutics Inc — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Summit Therapeutics Inc trades at $17.33 (market cap $14.33B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 3.5× Summit Therapeutics Inc's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EW | SMMT | |
|---|---|---|
Market Cap | $49.44B | $14.33B |
Volume | 3,508,027 | 8,167,213 |
Sector | Health | Health |
52-Week High | $95.18 | $26.38 |
52-Week Low | $72.65 | $12.43 |
Enterprise Value | $45.90B | $13.66B |
Typical Hold Time | — | 16 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
